Drug: PEMETREXED Injury: Malignant neoplasm progression Quarter: 2016Q3
Total Records: 6 Number of Pages: 1
Event ID | DRUGNAME | PT | Drug Manufacturer | Patient Age | Sex | Weight | Date (YYYYMMDD) | Country |
---|---|---|---|---|---|---|---|---|
124843623 | PEMETREXED | Malignant neoplasm progression | BRISTOL MYERS SQUIBB | 73.00 YR | M | 0 | 20160726 | JP |
126164092 | PEMETREXED | Malignant neoplasm progression | NOVARTIS | 49.00 YR | M | 0 | 20160809 | DE |
126406462 | Pemetrexed | Malignant neoplasm progression | ELI LILLY AND CO | 0.00 | M | 0 | 20160810 | US |
127497091 | PEMETREXED | Malignant neoplasm progression | NOVARTIS | 33.20 YR | F | 0 | 20160916 | US |
127548721 | Pemetrexed | Malignant neoplasm progression | ELI LILLY AND CO | 0.00 | F | 0 | 20160916 | US |
127746801 | Pemetrexed | Malignant neoplasm progression | ELI LILLY AND CO | 59.00 YR | F | 0 | 20160923 | US |
Total Records: 6 Number of Pages: 1